Thomas Catinazzo, Chief Financial Officer of Relay Therapeutics, Inc. (NASDAQ:RLAY), filed a Form 4 on October 30, 2026, disclosing a sale of 1,469 shares of common stock on October 28, 2026, to cover income tax withholding obligations arising from a restricted stock unit vesting event.

Key Highlights

  • Reporting person: Thomas Catinazzo, Chief Financial Officer of Relay Therapeutics, Inc.
  • Transaction: 1,469 shares of common stock disposed of (transaction code S) on October 28, 2026, at $18.62 per share.
  • Purpose: Sale was to cover income tax withholding obligations upon the vesting of 3,269 RSUs on October 27, 2026; the filing states the reporting person had no discretion with respect to such sale.
  • Post-transaction ownership: 103,665 shares of common stock beneficially owned directly following the transaction, including 3,269 shares underlying RSUs.
  • Filing date: October 30, 2026, signed by Soo-Yeun Lim as Attorney-in-Fact.

Relay Therapeutics CFO Catinazzo: RSU Vesting and Mandatory Tax-Cover Sale Details

According to the Form 4 filed with the U.S. Securities and Exchange Commission, Thomas Catinazzo, Chief Financial Officer of Relay Therapeutics, Inc., disposed of 1,469 shares of common stock on October 28, 2026, at a price of $18.62 per share. The filing states the sale was made to cover the reporting person's income tax withholding obligations upon the vesting of 3,269 restricted stock units on October 27, 2026. The filing further states that "the reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs."

Following the reported transaction, the filing discloses that Catinazzo directly holds 103,665 shares of common stock in beneficial ownership. The filing notes that this figure includes 3,269 shares underlying RSUs. No derivative securities transactions were reported in Table II of the filing. The Form 4 was signed on October 30, 2026, by Soo-Yeun Lim as Attorney-in-Fact for the reporting person.

Relay Therapeutics, Inc. is listed on NASDAQ under the ticker symbol RLAY. No other transactions or holdings were reported in this filing, and the filing does not indicate any amendment to a prior Form 4.

What Was Disclosed

Thomas Catinazzo, CFO of Relay Therapeutics, filed a Form 4 reporting the mandatory sale of 1,469 common shares at $18.62 on October 28, 2026, to satisfy tax withholding upon the vesting of 3,269 RSUs, leaving him with 103,665 shares beneficially owned directly.